Double treatment of severe hepatic veno-occlusive disease after allogeneic peripheral blood progenitor cell transplantation with recombinant tissue plasminogen activator.
Söhngen
D
D
Bauser
U
U
Boogen
C
C
Aul
C
C
Frieling
T
T
Germing
U
U
Schneider
P
P
Kobbe
G
G
Heyll
A
A
D058186:Acute Kidney Injury / Q000188:drug therapy / Q000209:etiology; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation; D006493:Heparin / Q000627:therapeutic use; D006504:Hepatic Veno-Occlusive Disease / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D015479:Leukemia, Myelomonocytic, Acute / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D012008:Recurrence; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D019172:Transplantation Conditioning / Q000009:adverse effects; D014184:Transplantation, Homologous
D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D005340:Fibrinogen; D006493:Heparin; D010959:Tissue Plasminogen Activator